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Abstract. In oncology, a rational approach to identify 
patients who are likely to benefit from therapy, already before 
initiation of treatment, is urgently required. Excision repair 
cross-complementation group 1 enzyme (ERCC1) has been 
proposed as a molecular predictor of clinical resistance to 
platinum-based chemotherapy. Other data suggest Tau protein 
expression as a predictor of clinical outcome in cancer patients 
treated with paclitaxel-based chemotherapy as low tau expres-
sion may render microtubules more vulnerable to paclitaxel. 
Therefore, the combination of ERCC1 and Tau may be a 
valuable predictor of sensitivity to platinum/paclitaxel treat-
ment. The primary aim of the study was to investigate whether 
ERCC1 and Tau protein expression correlates with patient 
outcome in newly diagnosed epithelial ovarian cancer (EOC) 
patients. Formalin-fixed, paraffin-embedded tissue sections 
from 227 newly diagnosed EOC patients were used for 
immunohistochemical staining for ERCC1 and Tau proteins. 
All patients received standard first-line combination platinum 
and paclitaxel chemotherapy. The patients were divided in 
a training set of 84 patients and an independent validation 
cohort of 143 patients. Neither ERCC1 nor Tau expression was 
associated with clinical response or platinum resistance in both 
the training and validation sets. Patients with ERCC1-positive 
tumors had significantly shortened progression-free and 
overall survival compared to patients with ERCC1-negative 
tumors, p<0.00001 and p=0.0006. In multivariate analysis 
ERCC1 also proved as an independent predictor of PFS and 
OS with HR of 3.86 and 1.98, respectively but the data could 
not be confirmed in the validation set. Tau expression was not 
associated with PFS or OS in this study. ERCC1 and Tau might 
serve as biomarkers of DNA repair and for paclitaxel sensi-
tivity but the present study could not validate ERCC1 or Tau 
protein expression in tumors as pre-treatment tools to predict 
sensitivity to first-line platinum/paclitaxel chemotherapy.
Introduction
Resistance to cytostatic drugs remains a major problem in 
clinical oncology. Most malignant tumors are sensitive from 
the start of treatment but develop drug resistance during the 
course of chemotherapy but a minor part are resistant already 
from the onset of treatment. The mechanisms behind chemo-
therapy resistance are multiple and complicated. The current 
knowledge in the field is far from sufficient to explain the 
biology. From a clinical point of view there is an urgent need 
of markers able to predict the effect of a certain regimen. The 
issue has been a central topic in clinical cancer research the 
last two decades but so far without much success. This is also 
true in ovarian cancer. Internationally, the combination of 
platinum and a taxane is still the cornerstone in the first-line 
treatment.
Despite an often initially good response to platinum-based 
chemotherapy the vast majority of tumors in patients with 
advanced disease will recur (1). In cases of platinum-resistant 
disease, the response to further platinum chemotherapy is 
negligible and usually only associated with side effects causing 
discomfort to the patient. Contemporary second line therapies 
are therefore palliative. A major challenge in oncology is 
therefore an urge to personalize the treatment more effec-
tively and conveniently for each patient based on the patients 
unique tumor biology, expectation of treatment responsive-
ness, prolongation of good quality of life and consideration of 
potential side effects. It would therefore be a rational approach 
to identify patients unlikely to benefit from chemotherapy 
already before initiation of treatment. Ovarian cancer is char-
acterized by a number of distinct diseases with heterogeneous 
biology not only among tumors but also intratumoral. Causes 
of platinum resistance are multifactorial, but one of the more 
compelling reasons of drug resistance is the ability of cancer 
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cells to repair DNA damage (2-4) caused by carboplatin. As 
alkylating agents, platinum compounds induce DNA damage 
by causing intrastrand/interstrand structural cross links, and 
formation of DNA adducts which are often lethal to the cell 
due to inhibition of DNA synthesis. If the cancer cells feature 
excessive DNA repair enzymes, they are better able to repair 
the chemotherapy-induced DNA damage and hence survive 
chemotherapy. One of these key DNA repair systems is exci-
sion repair cross-complementation group 1 (ERCC1), which is 
one of the essential proteins in the nucleotide excision repair 
(NER) pathway of several proteins that interact in a coor-
dinated way to recognize DNA damage and repair of DNA 
(5-7). Excision of the formed DNA adducts is carried out by 
nucleotide excision repair proteins (8) that recognize the DNA 
damage and excise the cytotoxic platinum-DNA adducts from 
the injured DNA strand. ERCC1 gene and protein expression 
have been found to be inversely correlated with response to 
platinum-based chemotherapy in ovarian cancer patients 
(9-11). In particular, several lung cancer studies (12-14) have 
shown that overexpression of ERCC1 is associated with poorer 
prognosis and chemotherapy resistance.
Resistance to the first line chemotherapeutic combination 
platinum/paclitaxel may also be associated with resistance to 
paclitaxel. Microtubule associated protein (MAP) Tau binds 
to β-tubulin in the same place as paclitaxel and may conse-
quently compete with this drug (15). Some studies focused 
on breast and gastric cancer revealed that patients with low 
expression of Tau protein benefit from paclitaxel therapy 
(16-20). Nevertheless, other studies, based on larger groups 
of breast cancer patients did not confirm these results (21,22). 
At the same time high Tau expression was indicated as a 
good prognostic factor in breast cancer (21), especially while 
co-expressed with estrogen receptor (22). There is very sparse 
data concerning the role of Tau protein in ovarian cancer (23).
To date, no validated tool exists that allows physicians to 
identify patients unlikely to respond to platinum and taxane 
agents to prevent patients suffering from unnecessary toxici-
ties.
The overall purpose of this study was to explore whether 
ERCC1 and Tau expression correlates with patient outcome in 
newly diagnosed epithelial ovarian cancer patients.
Multiple molecular biology studies have shown that the 
various histological subtypes do not share the same mutation 
pattern and do not have the same treatment response (24-26). 
The majority of epithelial ovarian cancer histology is the serous 
subtype. To make our study as uniform and unambiguous as 
possible, we therefore focused on examining patients with 
serous histology only.
Furthermore, the purpose was also to attempt to validate 
results obtained and therefore the present study was divided 
into a predefined training set and the findings from this 
dataset was sought for validation in a larger and independent 
validation set.
Materials and methods
Study population. Formalin-fixed, paraffin-embedded tumor 
tissue and clinical data were collected from chemotherapy-
naive patients with histological confirmed epithelial ovarian, 
primary peritoneal or fallopian tube cancer.
Patients were treated at four different institutions in 
Denmark (Departments of Clinical Oncology at Aalborg, 
Herning, Odense and Vejle Hospitals) and in one institution 
in Poland (Department of Oncology, Military Institute of 
Health Services, Warsaw, Poland). The data from the patients 
included in the training set have previously been published 
(11,23). Unlike the previous report, the present study only 
included patients with serous histology and the follow-up time 
is much longer with mature overall survival data.
The study was carried out in compliance with the Helsinki II 
Declaration. The Regional Scientific Ethics Committee for 
Southern Denmark and the Danish Data Protection Agency 
approved the study according to Danish law. The Local 
Research Ethics Committee approved the study according to 
Polish law.
All specimens were collected prior to chemotherapy, either 
as a biopsy before neoadjuvant chemotherapy or as tumor 
tissue removed at up-front debulking surgery. Patients were 
treated with combination chemotherapy with carboplatin 
(AUC5/AUC6) and paclitaxel (175 mg/m2) or cisplatin (75 mg/
m2) and paclitaxel (135 mg/m2) for some of the Polish patients 
treated in the early 2000s. Treatment was administered every 
3 weeks for six cycles. From each patient one representative 
formalin-fixed, paraffin-embedded tissue block was selected 
and sections at 3.5 µm were cut.
ERCC1 immunohistochemistry. The sections were initially 
deparaffinized, rehydrated and blocked for endogenous perox-
idase with 3% H2O2 followed by heat induced epitope retrieval 
in Tris-EGTA buffer pH 9.0 in microwave oven.
The immunostaining was performed on the Dako auto-
stainer link 48 with the monoclonal mouse antibody against 
human full-length ERCC1 protein (clone 8F1, Thermo 
Scientific, Cheshire, UK, code no. MS-671-P, 1:1,000 dilu-
tion). Detection of the immunoreaction was obtained using the 
Super Sensitiv™ Polymer-HRP IHC kit (BioGenex, Fremont, 
CA, USA) as described previously (10). Please refer to Table I 
for further details.
The lot numbers of the antibody and of the detection kit 
used for the validation set were not the same as used for the 
training set. Therefore, adjustments were made in order to 
obtain similar staining intensity as for the training set. We 
performed the optimization carefully on different tissues 
and patient samples and finally, we restained a small group 
of 11 samples from the training set, to ensure that the origi-
nally staining could be reproduced. Three different lots of the 
primary antibody and two lots of the detection kit were tested 
and we found that there was a minor lot to lot variation for the 
ERCC1 antibody, but there were significant lot to lot variations 
for the detection kits. As a consequence, we had to dilute the 
primary antibody 3-fold. We stained all samples in the valida-
tion set with the same lot of ERCC1 and detection kit. Under 
these conditions we could reproduce the staining from the 
training set.
The slides were scored as described by Olaussen et al (14) 
and similar to our previous studies (10,11). Scoring of the 
immunohistochemistry results was generated by multiplication 
of the values for the percentage of immunopositive epithe-
lial tumor cells and for staining intensity. In brief, staining 
intensity was graded 0-3, with 3 as the highest intensity. The 
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percentage of positive tumor cells in each slide were scored 
as 0 if 0% of the tumor cells were positive, 0.1 if 1-9%, 0.5 if 
10-49% and 1.0 if ≥50% were positive. A semi-quantitative 
H-score for cutoff point was calculated by multiplying the 
staining intensity with the percentage score and the tumor was 
scored as positive when the H-score was >1.0 as also described 
in previous reports (10,11,14) for separating ERCC1-positive 
tumors from ERCC1-negative tumors. The interpretation 
of ERCC1 expression was done by a senior gynecological 
pathologist (M. Waldstrøm). At the time of interpretation, the 
authors had no knowledge of the clinical data.
Tau immunohistochemistry. Immunostaining was performed 
with anti-Tau polyclonal rabbit antibody that recognizes all 
isoforms of human Tau irrespectively of its phosphoryla-
tion status (1:100 dilution; code A 0024; Dako Cytomation, 
Glostrup, Denmark). Formalin-fixed, paraffin-embedded 
3.5-µm sections of ovarian cancer were incubated with 
anti-Tau antibody for 30 min in room temperature. Anti-rabbit 
horseradish peroxidase-labeled secondary antibody was 
used to generate the signal (code K 4002; Dako EnvisionTM+ 
System). Normal ovarian epithelium serving as control tissue 
was derived from a benign ovarian cyst in a 51-year-old patient. 
Omission of primary antibody served as a negative control. 
Specimens were assessed by means of light microscope with 
x20 magnification lens. Tau staining of tumor cells was scored 
according to a previous report (4) with our modification as 
follows: IHC score 0, no staining; 1+, poor focal staining or 
very poor diffuse staining; 2+, average diffuse staining or 
strong staining in <25% cells; 3+, strong staining in ≥25% 
of tumors cells. Tau expression was recorded as negative 
(0 and 1+) or positive (2+ and 3+). This dichotomization of 
staining results was determined by using staining intensity 
of normal epithelial cells as a reference. Slides were scored 
without knowledge of the clinical outcome.
Statistical analyses. The χ2 test was used for testing a possible 
association between ERCC1/Tau immunohistochemistry and 
clinicopathological parameters and response to chemotherapy.
Progression-free survival was defined as the time from 
date of diagnosis (date of primary surgery or diagnostic 
biopsy) until disease recurrence or death from any cause, 
whichever came first. Overall survival was calculated as the 
interval from the time of diagnosis until death from any cause. 
Univariate overall survival analysis was performed using the 
Kaplan-Meier method and log-rank statistics for comparison 
of survival plots. Multivariate overall survival analysis was 
determined by the Cox regression model. Graphical checks of 
proportional hazards assumption were made for all variables 
before entering the variables into the Cox regression model. 
The parameters entered in the Cox analysis were ERCC1 status 
(negative and positive), Tau status (negative and positive), 
FIGO stage, grade and residual disease status as categorical 
variables and age at diagnosis as a continuous variable. FIGO 
stage was divided into stage I/II vs. stage III/IV, grade into 
grade 1 vs. grade 2/3/not-graded to avoid too many parameters 
entered into the Cox model according to the number of events 
if not merged into fewer variables. A value of p<0.05 was 
considered statistically significant. Statistical analyses were 
performed with the NCSS software (version 2007, Kaysville, 
Utah, http://www.ncss.com).
Results
Patient characteristics. Paraffin-embedded tumor specimens 
were obtained from all 227 patients enrolled into the two 
Table I. Antibodies used for ERCC1 and Tau staining.
Antibody ERCC1 clone ERCC1 clone Tau
 8F1 (training) 8F1 (validation)
Producer Neomarkers Thermo Scientific Dako Cytomation
  (Neomarkers)
Code nr/Cat nr MS-671-P MS-671-P A 0024
Antibody dilution  1:300 1:1,000 1:100
Deparaffinazation Tissue-Clear® Tissue-Clear® Xylene 2x10 min; ethanol: absolute,  
   96%, 70%, 50%, water - each 2 min
Epitope retrieval MWO/EGTA/pH9 MWO/EGTA/pH9 None (according to the manufacturer's
 15 min boiling/ 15 min boiling/ product specification)
 15 cooling RT 15 cooling RT
Time 30 min room temperature 30 min room temperature 30 min room temperature
Amplification Super enhancer (from Super enhancer (from None
 the detection system) the detection system)
Detection system* Super Sensitiv™ Polymer-HRP Super Sensitiv™ Polymer-HRP K 4002; Dako EnvisionTM+ System
 IHC kit (BioGenex, no IHC kit (BioGenex, no
 QD430-XAKE) QD430-XAKE)
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studies (N=84 for the training study and N=143 for the valida-
tion study).
Patients included in the training set were all consecutively 
included at the Danish hospitals during the period 2005-
2007. The validation cohort consisted of all patients from 
the Polish center (included in the period 2001-2009) and 
of patients from the Danish centers consecutively enrolled 
during 2007-2010. The patient characteristics are outlined in 
Table II.
Six cycles were administered to 81.5% of the patients and 
98% received at least three cycles. Nineteen patients received 
more than six cycles due to an expectation of a further tumor 
response with prolonged treatment up to a maximum of 
nine cycles.
The predictive value of ERCC1 and Tau protein expression. 
Staining of ERCC1 and Tau was not significantly associated 
with each other (p>0.05, Fisher's exact test). Furthermore, 
neither ERCC1 nor Tau was associated with age, histological 
grade, FIGO stage, or residual tumor size (data not shown).
Thirty-six percent of patients with positive ERCC1 expres-
sion in the training set progressed during first line chemotherapy 
compared to progression in only eight percent of patients with 
negative ERCC1 expression (p=0.05, Table IIIA) although the 
numbers of patients progressing during first line chemotherapy 
were rather small.
However, patients with early relapse and platinum resis-
tance had highly significantly increased levels of ERCC1 
expression (p=0.0004, Table IIIB). Platinum resistance was 
defined as recurrence within 6 months after completion of first 
line platinum-based chemotherapy or progression during the 
first line platinum-based chemotherapy.
Positive ERCC1 staining was not significantly associated 
with treatment outcome in the validation set. Tau expression 
was not associated with clinical response or with platinum 
resistance in the training or validation set.
The prognostic value of ERCC1 and Tau protein expression. 
At the time of the analysis, 63 patients were deceased in the 
training set material. For the 21 patients still alive, the median 
Table II. Patient characteristics.
Clinicopathological parameters Training set Validation set p-value
  N=84 N=143
Age median 63.5 60.6 0.13
Age range 32-79 31-89
FIGO stage   0.20
 I   4   (4.8%)   11    (7.7%)   
 II 10 (11.9%)   11    (7.7%)
 III 56 (66.7%)   83 (58.0%)
 IV 14 (16.7%)   38 (26.6%)
Grade   0.14
 1   3   (3.7%)     8   (7.4%)
 2 29 (35.4%)   49 (45.4%)
 3 50 (61.0%)   51 (47.2%)
  (Not graded - e.g. clear cell, (Not graded - e.g. clear cell,
   or biopsy only: 2) or biopsy only: 35)
Residual tumor   0.0001
 0 cm 21 (25.6%)   74 (54.8%)
 <1 cm 17 (20.7%)   16 (11.9%)
 ≥1 cm 44 (53.7%)   45 (33.3%)
  (Data not available: 2) (Data not available: 8)
ERCC1 staining   0.06
 Negative 73 (86.9%) 106 (76.8%)
 Positive 11 (13.1%)   32 (23.2%)
   (Staining not done: 5)
Tau staining   0.24
 Negative 24 (29.3%)   44 (37.3%)
 Positive 58 (70.7%)   74 (62.7%)
  (Staining not done: 2) (Staining not done: 25)
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follow-up time was 70 months (range, 53-87 months). In the 
validation set, 63 patients were deceased at censoring time 
and the median follow-up for the 80 patients still alive was 
36 months (range, 16-110 months). There were no statistical 
differences in PFS or OS between the training and the valida-
tion sets (p=0.10 and 0.16, respectively).
Training set. Patients with ERCC1-positive tumors had 
significantly shortened progression-free survival compared 
to patients with ERCC1-negative tumors, p<0.00001 (Fig. 1). 
The Kaplan-Meier estimate of median PFS for patients with 
ERCC1-positive tumors was 8.1 months (6.1-8.9 months) 
95% CI while the median PFS of patients with ERCC1-negative 
tumors was 13.4 months (11.9-21.1 months) 95% CI.
The difference in PFS also translated into a significant 
advantage in overall survival for patients with ERCC1-negative 
tumors, p=0.0006 and with >2 years difference in median 
OS (16.8 vs. 42.9 months, Fig. 1). Tau expression had no 
significantly association with PFS or OS, p=0.87 and 0.59, 
respectively.
Validation set. For ERCC1, the findings from the training set 
could not be confirmed in the validation set as there were no 
significantly differences in PFS or OS according to ERCC1 
tumor expression (p=0.55 and 0.90, respectively, Fig. 1). For 
Tau expression the findings were the same as in the training 
set, with no influence of Tau expression on PFS or OS.
Multivariate analysis. The Cox proportional hazard model was 
used in order to study the independent effect of ERCC1 and 
Tau. FIGO stage, suboptimal debulking (residual tumor <1 and 
≥1 cm) and positive ERCC1 (HR 5.71, 95% CI; 2.65-12.3) were 
found to be independently associated with worse PFS in the 
training set (p=0.021, p=0.003/0.002 and p<10-3, respectively).
However, in the validation set, only FIGO stage and residual 
tumor were independent predictors of PFS (Table IVA). FIGO 
stage (p=0.028), residual tumor <1 and ≥1 cm (p=0.031 and 
0.002, respectively) and ERCC1 (p=0.008) were also associ-
ated with OS in the training set. Again, ERCC1 and Tau were 
not associated with OS in the validation set. The results of the 
multivariate OS analysis are summarized in Table IVB.
Table III. Association between ERCC1 expression and chemotherapy response (A)/platinum resistance (B).




 Training set Validation set
 P=0.05 P=0.72
 ------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------
Response Negative Positive All Negative Positive All
 ERCC1 IHC ERCC1 IHC  ERCC1 IHC ERCC1 IHC
Complete response 43 (66%)   5 (46%) 48 38 (48%) 10 (46%)   48
Partial response 14 (22%)   2 (18%) 16 28 (35%)   8 (36%)   36
No change   3   (5%)   0   (0%)   3   8 (10%)   1   (5%)     9
Progression   5   (8%)   4 (36%)   9   6   (8%)   3 (14%)     9
Non evaluable
for response      8     41
All 65 11 84 80 32 143
B, Association between ERCC1 immunohistochemistry and platinum resistance (platinum resistance defined as recurrence 
within 6 months after completion of first line platinum-based therapy)
 ERCC1 status
 -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 Training set Validation set
 P=0.0004 P=0.58
 ------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------
Platinum resistance Negative Positive All Negative Positive All
 ERCC1 IHC ERCC1 IHC  ERCC1 IHC ERCC1 IHC
Platinum-sensitive 48 (66%)   1   (9%) 49 75 (71%) 21 (66%)   96
Platinum-resistant  25 (34%) 10 (91%) 35 31 (29%) 11 (34%)   42
All 73 11 84 106 32 138
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Figure I. Progression-free and overall survival according to Tau and ERCC1 status. (A) Univariate progression-free and overall survival analysis according to 
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Table IV. Multivariate progression-free survival (A) and overall survival (B) analysis for both the training and validation set.
A, Overall survival
 Training set Validation set
 ------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------
PFS HR 95 % CI p-value HR 95 % CI p-value
Age 0.99 0.96-1.02 0.622 1.00 0.98-1.02 0.892
FIGO stage
  I/II 1.00   1.00
  III/IV 2.71 1.16-6.34 0.021 4.43 1.54-12.8 0.006
Tumor grade
 1 1.00   1.00
 2/3/not graded 2.82 0.37-21.3 0.315 1.66 0.58-4.70 0.342
Residual tumor
  0 cm 1.00   1.00
 <1 cm 3.73 1.56-8.93 0.003 1.73 0.85-3.50 0.129
 ≥1 cm 3.14 1.54-6.42 0.002 2.10 1.21-3.64 0.009
ERCC1 staining
 Negative 1.00   1.00
 Positive 5.71 2.65-12.3 <10-3 0.85 0.45-1.59 0.611
Tau staining
 Negative 1.00   1.00
 Positive 0.63 0.35-1.14 0.124 1.30 0.80-2.10 0.290
B, Multivariate OS analysis
 Training set Validation set
 ------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------
OS HR 95 % CI p-value HR 95 % CI p-value
Age 1.01 0.98-1.04 0.540 1.02 0.99-1.04 0.152
FIGO stage 
    I/II 1.00   1.00
 III/IV 3.20 1.13-9.01 0.028 9.26 1.23-69.9 0.031
Tumor grade
 1 1.00   1.00
 2/3/not graded 1.42 0.18-10.9 0.735 2.73 0.66-11.5 0.172
Residual tumor 
 0 cm 1.00   1.00
 <1 cm 2.92 1.10-7.77 0.031 1.82 0.81-4.11 0.146
 ≥1 cm 3.75 1.61-8.74 0.002 1.73 0.91-3.28 0.096
ERCC1 staining
 Negative 1.00   1.00
 Positive 2.69 1.30-5.56 0.008 0.59 0.25-1.43 0.245
Tau staining
 Negative 1.00   1.00
 Positive 0.76 0.40-1.44 0.392 1.19 0.66-2.14 0.569
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Discussion
Management of patients with relapsed ovarian cancer consti-
tutes a therapeutic challenge. Predicting and overcoming 
chemotherapy resistance and platinum-induced resistance in 
particular might be one of the key issues for improving the 
efficacy of ovarian cancer therapies, both in the first-line 
setting and in the treatment of relapses.
Previously published reports from our group have focused 
on ERCC1 as one of these potential tools for in advance to 
pinpoint patients who are likely not to benefit from platinum-
based chemotherapy if they have high expression of ERCC1 
(10,11,27). Specifically, it is striking how large the survival 
difference is between patients with ERCC1-positive and 
ERCC1-negative tumors concerning both PFS and OS in 
the training set, which is identical with the patient material 
included in a previous report (11). Although the previous report 
included all epithelial histological subtypes. In the present 
report, this patient cohort is now updated with much longer 
follow-up which further confirms the data as described in 
the previous report in which PFS but not OS (p=0.099 in 
univariate analysis) on the publication time were signifi-
cantly different in patients with ERCC1-positive tumors 
compared to ERCC1-negative tumors. Now, the OS has as 
well become significantly disadvantageous (p=0.0006 and 
0.008 in univariate and multivariate OS analysis, respec-
tively) for patients with ERCC1 overexpression presumably 
because of longer follow-up and more mature data. It is there-
fore surprising that the data can not be validated. There are 
several considerations on possible causes for this. The most 
obvious reason is, of course, that ERCC1 is not an unambig-
uous and reliable marker of platinum resistance. Data have 
so far been inconsistent and recently, a report from another 
group, in agreement with our present report, also described 
that ERCC1 expression was unable to predict platinum resis-
tance (28). This GOG study consisted of a heterogeneous 
group of 408 patients treated with seven different platinum-
containing regimens and moreover, they used a different 
ERCC1 antibody (FL297 polyclonal antibody) for immuno-
histochemical detection. Thirdly, the immunohistochemical 
scoring method was somewhat different as the scoring of 
ERCC1 was performed in a binary fashion where any nuclei 
staining in a specimen was defined as positive and lack of any 
nuclei staining as negative, making a straight comparison of 
studies difficult. Cancer biology is not simple, and ERCC1 is 
only one of the proteins involved in a complex pathway of the 
NER system with contributions from many other players also 
likely to influence DNA repair.
Another potential criticism of the present study is an 
ongoing scientific discussion concerning the quality of the 
used ERCC1 antibody, which is also stated by the authors 
of the GOG report (28) and their viewpoint on why they can 
not demonstrate a clinical importance of ERCC1 staining in 
the GOG study. A report by Bhagwat et al (29) argued that 
the most commonly used antibody, 8F1, which was also the 
one used in our study and in many others was not suitable 
for immunodetection in tissue and recommended the use of 
the polyclonal FL297 antibody. This conclusion was drawn 
on the basis of an observed additional band with extremely 
close molecular weight in western blots. As a response to this 
Olaussen and Soria (30) reinvestigated the signal from the 
8F1 antibody and did not observe a higher band very close to 
ERCC1 suggesting that it is rarely present in carcinoma cells. 
The 8F1 signal also correlated with ERCC1 mRNA expres-
sion in the cells suggesting antibody specificity. Consequently, 
Olaussen and Soria argued that the 8F1 antibody is an accept-
able tool to determine nuclear ERCC1 protein expression in 
human formalin-fixed paraffin-embedded solid tumors of 
epithelial origin, whereas FL297 lead to a puzzling cyto-
plasmic staining.
None of the above explanations holds true in the present 
study as they do not explain the difference between the training 
and the validation set.
Another possibility may have its origin in diversity of 
the two sets of material. In the training set there were far 
less optimal debulked patients (26%) compared with the 
validation set which was a more recent and more extensive 
surgically operated cohort with nearly twice as many patients 
operated with optimal debulking (55%). One can speculate 
whether ERCC1 and Tau have greater significance in patients 
with residual tumor as it may be assumed that the effect 
related to chemotherapy depends on the size of the residue 
after surgery. The issue is of general importance as the value 
of predictive markers may vary considerably with tumor 
stage. The predictive value in early stage tumors of a disease 
allocated for adjuvant treatment may well be different from 
that of advanced disease with major residual tumor. This may 
at least partly explain why the results from the training set 
were not confirmed.
ERCC1 and Tau might serve as biomarkers of DNA repair 
in tumors and for paclitaxel sensitivity, respectively, but the 
present study could not confirm ERCC1 or Tau protein expres-
sion in tumors as pre-treatment tools to predict sensitivity to 
first line platinum/paclitaxel chemotherapy.
The results presented here illustrate a major problem in 
the search for biomarkers and their validation. There is an 
enormous amount of literature identifying predictive and/or 
prognostic markers but most studies are based on insufficient 
patient material or never validated. Consequently, very few have 
been accepted for clinical use. The situation calls for markers 
to be incorporated in prospective and preferably randomized 
clinical trials as a prerequisite for clinical routine applications.
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